摘要
【目的】比较利拉鲁肽和艾塞那肽治疗2型糖尿病（T2DM）的有效性和安全性。【方法]78例T2DM患者分为两组：利拉鲁肽组采用利拉鲁肽联合二甲双胍治疗，艾塞那肽组采用艾塞那肽联合二甲双胍治疗，均治疗16周。比较两组患者体质量指数（BMI）、空腹血糖（FPG）、餐后2小时血糖（2hPG）、糖化血红蛋白（HbA1c）水平、空腹胰岛素（FINS）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL—C）、胰岛素分泌指数（HOMA-IS）、胰岛素抵抗指数（HOMA-IR）及不良反应的发生率。【结果】两组治疗前HbA1c、FPG、2hPG、BMI、TG、TC、HDL—C、HOMA—IR、HOMA_Is等比较无显著差异（P〉0．05）；利拉鲁肽组治疗后BMI、FPG、2hPG、HbA1c均显著降低（P〈0．01），而HOMA-IS显著增高（P〈0．01），艾塞那肽组治疗后BMI、FPG、2hPG、LDL-C、HOMA—IR、HbA1c均较治疗前明显下降（P〈0．05）；但利拉鲁肽组FPG、2hPG、下降幅度显著高于艾塞那肽组（P〈0．05），LDL-C下降幅度显著低于艾塞那肽组（P〈0．01），而两组HbA1C、BMI、TG、TC、HDL—C、HOMA_IR、HOMA—IS等指标的变化幅度无显著差异（P〉0．05）。两组均无严重不良反应发生。【结论】利拉鲁肽和艾塞那肽联合二甲双胍治疗T2DM均疗效确切，安全性好，但利拉鲁肽对FPG、2hPG下降幅度娶优干干茧寰那肽．而芷寰那肽降低LDL—C水平方面优于利拉鲁肽。
[Objective] To observe the efficacy and safety of Liraglutide and Exenatide in patients with type 2 diabetes mellitus （T2DM）. [Methods] 78 patients with T2DM were involved in this study for 16 weeks therapy and divided into two groups： the Liraglutide group and the Exenatide group. All patients took with same dosage of metformin therapy simultaneously. The effects of the two groups on body mass index （BMI） ,fasting blood glucose （FPG）, 2-hour postprandial glucose （2hPG）, glycosylated hemoglobin （HbAlc）, fasting insulin （FINS）, triglyceride （TG）, total cholesterol （TC）, low density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol （HDL-C）, insulin secretion index （HOMA-IS）, insulin resistance index （HOMA-IR） and the incidence of adverse reaction were observed and compared. [Results] Before treatment , HbAle, 2hPG, FPG, BMI, TG, TC, HDL-C, HOMA-IR and HOMA-IS of the two groups had no signifieant difference （ P 〈0.05） ; After treatment, BMI, FPG, 2hPG, HbAlc in the Liraglutide group were significantly decreased （ P 〈0.01）, and the HOMA-IS increased dramatically（ P 〈0.01）. After treatment, the FPG,, 2hPG, LDL-C, HOMAqR, HbAlc and BMI in the Exenatide group were significantly decreased （ P 〈0.05） ; However, the deereasing rate of the FPG and 2hPG in the Liraglutide group were significantly higher than those in the Exenatide group （ P 〈0.05）, and the decrease rate of LDL-C was significantly lower than that in Exenatide group （ P 〈0.01） ; The BMI, TG, HbAlc, TC, HDL-C, HOMA-IR, HOMA-IS of the two groups had no significant difference （ P 〉0.05）, and no serious adverse reactions occurred in both of the two groups, [Conclusion]Liraglutide and Exenatide combined with metformin in the treatment of T2DM were effective and safe, but Liraglutide is superior in the decrease of FPG and 2hPG to Exenatide, while Exenatide performed better in LDL-C decreasing than Liraglutide.
出处
《医学临床研究》
CAS
2015年第9期1725-1727,共3页
Journal of Clinical Research
